{"filing":{"accession_number":"0001213900-26-088435","cik":"0001795091","ticker":"OSTX","company_name":"OS Therapies Inc","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-06","primary_document":"ea0301485-8k_ostherapies.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026088435/ea0301485-8k_ostherapies.htm"},"events":[{"id":27331,"run_id":24894,"accession_number":"0001213900-26-088435","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.93,"summary":"OS Therapies entered into a securities purchase agreement on August 10, 2026, to issue senior secured convertible promissory notes totaling up to $10,000,000 in a private placement, with the initial tranche of $5,000,000 already closed. The offering includes common stock, pre-funded warrants, and five-year warrants, creating substantial dilution to existing shareholders through unregistered sales of equity securities under Section 4(a)(2) and Regulation D exemptions.","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28797,"accession_number":"0001213900-26-088435","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"OS Therapies entered into a securities purchase agreement on August 10, 2026, to issue senior secured convertible promissory notes totaling up to $10,000,000 in a private placement, with the initial tranche of $5,000,000 already closed. The offering includes common stock, pre-funded warrants, and five-year warrants, creating substantial dilution to existing shareholders. This is a classic dilutive private placement of unregistered equity securities, material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:57:12.276940+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28798,"accession_number":"0001213900-26-088435","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, with incorporation by reference to Item 1.01 (which typically covers material agreements, acquisitions, or financing transactions). The Item 2.03 heading and reference structure indicate a debt issuance or similar financial obligation has been created. Without access to Item 1.01 details, debt_issuance is the most probable classification for a direct financial obligation disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:57:12.276940+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28799,"accession_number":"0001213900-26-088435","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities by OS Therapies Inc, including common shares, convertible notes, and warrants sold to accredited investors under Section 4(a)(2) and Regulation D exemptions. The disclosure of convertible notes and warrants exercisable for common stock, combined with the reference to Item 1.01 (which typically covers material acquisitions or transactions), indicates a dilutive private placement that would materially affect existing shareholders through equity dilution and potential voting power reduction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:57:12.276940+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28797,"accession_number":"0001213900-26-088435","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"OS Therapies entered into a securities purchase agreement on August 10, 2026, to issue senior secured convertible promissory notes totaling up to $10,000,000 in a private placement, with the initial tranche of $5,000,000 already closed. The offering includes common stock, pre-funded warrants, and five-year warrants, creating substantial dilution to existing shareholders. This is a classic dilutive private placement of unregistered equity securities, material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:57:12.276940+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-08-12"},{"id":28798,"accession_number":"0001213900-26-088435","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, with incorporation by reference to Item 1.01 (which typically covers material agreements, acquisitions, or financing transactions). The Item 2.03 heading and reference structure indicate a debt issuance or similar financial obligation has been created. Without access to Item 1.01 details, debt_issuance is the most probable classification for a direct financial obligation disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:57:12.276940+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-08-12"},{"id":28799,"accession_number":"0001213900-26-088435","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities by OS Therapies Inc, including common shares, convertible notes, and warrants sold to accredited investors under Section 4(a)(2) and Regulation D exemptions. The disclosure of convertible notes and warrants exercisable for common stock, combined with the reference to Item 1.01 (which typically covers material acquisitions or transactions), indicates a dilutive private placement that would materially affect existing shareholders through equity dilution and potential voting power reduction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:57:12.276940+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-08-12"}]}